Drug Type Universal CAR-T |
Synonyms LMY-922 |
Target |
Action inhibitors, modulators |
Mechanism BAFF-R inhibitors(B-cell activating factor receptor inhibitors), BCMA inhibitors(B-cell maturation protein inhibitors), TACI modulators(Tumor necrosis factor receptor superfamily member 13B modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Chronic Lymphocytic Leukemia | Preclinical | United States | 01 Jan 2026 | |
| Rheumatoid Arthritis | Preclinical | United States | 01 Jan 2026 |





